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Multidrug resistant (MDR) strains of the Gram-negative
pathogenic bacterium, Escherichia coli, particularly
fluoroquinolone-resistant strains, are the major causative
agents for hospital acquired (HA) infections, as well as
epidemics linked to gastrointestinal (GI) and urinary
tracts in the non-hygienic communities of most devel-
oping countries. The prevalence of multidrug resistance
among 1642 strains of E. coli, isolated from clinical
samples of patients with GI infections in a hospital over
39 months (November 2009eJanuary 2013) is recorded,
along with sensitivity patterns to 23 currently used anti-
biotics, including third-generation cephalosporins and
fluoroquinolones with disc-diffusion method. A total of
1642 strains of E. coli were isolated from the clinical
samples, of which 810 isolates were from CA samples and
832 isolates were from hospitalized patients during the
study period. Of the 810 CA isolates, 567 strains were
resistant to fluoroquinolone antibiotics; of the 832 HA
isolates, 575 strains were fluoroquinolone-resistant,
independently. Minimum inhibitory concentration
values of fluoroquinolones (ciprofloxacin and levo-
floxacin) against the isolated E. coli strains confirmed the
resistance in the current/coveted treatment options. Pa-
tients with other bacterial infections had relatively higher
chances of becoming infected with fluoroquinolone-
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Suffering from several chronic uncontrollable bacterial
infections often leads to terminal diseases, at least in
immune-compromised/aged individuals, if the innards
become infected. On analysis, it is found that drug-resistant
bacteria are the causative organism of morbidity and mor-
tality.1 Indeed, pathogenic bacteria gain multidrug resistant
(MDR) traits due to their simple genomes, and
concomitantly natural consortia of bacteria help mediate
their evolutionary exchanges of genetic materials.2 As
antibiotics are microbial in origin, targeted microbes
develop resistance to the applied antibiotics intrinsically;
the mutation frequency of antibiotic-resistance is recorded
as one in 106 e 108 cells.3 However, small and clean a
hospital be it may, the chance of spreading pathogenic
bacteria to health personnel, who often serve as reservoirs
along with hospitalized patients, should be ample aside
from the spread from fomites and devices.4 Furthermore,
nosocomial infections of patients with burn and surgical
injuries, as well as life-threatening urinary tract infections
or even enteropathogenic episodes, frequently lead tohis is an open access article under the CC BY-NC-ND license
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S. Rath and R.N. Padhy 505bacteraemia/septicaemia.5,6 Any infection in a patient must
be controlled forthwith, and the surveillance of a group of
pathogens can be undertaken at a hospital for the
estimation required for assurance on prescribed antibiotics.
The evolutionary capabilities of a few pathogenic Gram-
negative (GN) bacteria are so versatile that notorious pan-
drug resistant (PDR; some strains of these bacteria are
resistant to almost all contemporary antibiotics) strains have
emerged; they are identified mainly as Escherichia coli,
Enterobacter aerogenes and Klebsiella pneumoniae.7,8 The
outbreak of accredited MDR bacterial strains and their
rapid spread affects the cost of hospitalization and the
public health sector, leading to the urgency behind the
implementation of some avant-garde drugs as
antimicrobials.
Fluoroquinolones are broad-spectrum antibiotics that are
used to treat several GN and Gram-positive (GP) bacterial
infections. Since 1960, fluoroquinolones have become prev-
alent in the treatment of urinary, respiratory, gastrointes-
tinal, urogenital, intra-abdominal, and skin infections. E. coli
infections, especially in the urinary and gastrointestinal
tracts, are frequently addressed with fluoroquinolones. The
emergence of quinolone-resistance during treatment was first
reported in Staphylococcus aureus, particularly along with
the methicillin-resistant S. aureus (MRSA) and Pseudomonas
aeruginosa. Fluoroquinolone resistance emerged rapidly and
spread to Gram-positive (GP) and GN bacteria in hospitals,9
with minimal inhibitory concentration (MIC) values
inhibiting 90% of pathogen growth specifically over a
broad range from  0.015 up to  128 mg/L
fluoroquinolones.9 Drug-resistant subpopulations of patho-
gens became prevalent two decades ago and have remained
almost unnoticed. Recent surveillance studies demonstrated
that fluoroquinolone resistance rates have continued to in-
crease, affecting patient management and necessitating the
need for changes in the current treatment guidelines.10
The aim of this study was to evaluate the occurrence of
fluoroquinolone resistance, particularly in E. coli causing
nosocomial and community-acquired infections in patients
over a period of 39 months (November 2009eJanuary 2013).
The antibiotic resistance patterns of these isolates against 23
antibiotics along with fluoroquinolones used in the study is
crucial to hospital management, as empiric therapy is often
needed for E. coli infections in the GI and urinary tracts.Materials and Methods
Isolation, identification and antibiotic sensitivity of E. coli
isolates
IMS and Sum hospital is a philanthropic teaching hos-
pital situated in Bhubaneswar, the capital city of Odisha
state, India. Patients from all walks of life, from slum-
dwellers to socialites, attend this hospital. Clinical samples
(urine and stool samples) collected from the outpatient
department (OPD) were taken as community acquired (CA)
samples. Collected clinical samples from wards, cabins,
intensive care units (ICU) and neonatal intensive care units
(NICU) of the hospital were referred to as hospital acquired
(HA) samples for the isolation of E. coli strains. Of the total
12,846 clinical samples obtained over a period of 39 months,only 7194 samples yielded both GN and GP bacteria. GN
bacteria were cultured on MacConkey (MC) agar and
cysteine deoxycholate electrolyte deficient (CLED) agar
(HiMedia, Mumbai). The E. coli strain MTCC strain num-
ber 443, was used as the reference strain for all experiments.
Antibiotic susceptibility tests were performed using Kirbye
Bauer’s disc diffusion method.11 This study was performed
after being approved by the institutional ethical board.
Determination of MIC values of fluoroquinolones antibiotics
The MIC values of two frequently used fluoroquinolone
antibiotics, ciprofloxacin and levofloxacin against 50 drug-
sensitive strains and 50 resistant strains of E. coli were
determined by micro-broth dilution method using 96-well
microtiter plates, as described elsewhere.12 The results were
interpreted using the standard breakpoint values suggested
by the clinical and laboratory standards institute and the
2014 guidelines of the European committee of
antimicrobial susceptibility testing.13,14
Statistical analysis
Statistical analysis was performed using the Statistical
Package for Medical Science version 17.0 (SPSS Inc., IL) and
Microsoft Excel.
Results
Isolation and identification of E. coli strains
A total of 1642 strains ofE. coliwere isolated from clinical
samples, of which 810 isolates were from CA samples and
832 isolates were from hospitalized patients, taken during the
study period. Of the 810 CA isolates, 567 strains were
resistant to fluoroquinolone antibiotics. Similarly, of the 832
HA strains, E. coli 575 strains were fluoroquinolone-
resistant, independently. When grown on MC agar,
medium-sized colonies coloured bright pink (due to inherent
lactose fermentation) were seen, and when grow on CLED
agar, large, round yellow coloured colonies were seen, con-
firming the presence of E. coli.
Antibiotic susceptibility pattern of E. coli isolates
The antibiotic susceptibility patterns of isolated E. coli
strains were studied over the period of 39 months using 23
antibiotics. HA E. coli strains were found to be highly
resistant to, in descending order, gentamicin (98%), cefepime
(82%), nitrofurantoin (94%) and norfloxacin (87%) and
were least resistant to imipenem (21%). Similarly, CA E. coli
isolates were resistant to co-trimoxazole (94%), followed by
gentamicin (91%), ciprofloxacin (89%), amikacin (87%) and
cefotaxime (87%), and were least resistant to imipenem
(17%) and levofloxacin (25%) (Table 1). The resistance
percentage values clearly support that there is high
occurrence of ESBL and fluoroquinolone-resistant strains
of E. coli isolates in hospital and community settings.
Moreover, resistance to aminoglycosides and carbapenems
(imipenem and meropenem) were recorded, which would
further complicate the treatment regimen for an infection, as
Table 1: Resistance percentages of E. coli to 23 antibiotics of eight classesa.
Antibiotic group Antibiotics (mg/disc) Resistance
(in %) E. coli
HA CA
Aminoglycosides Amikacin 30 81 87
Gentamicin 10 98 91
Netillin 30 74 65
b-lactams Amoxyclav 30 82 85
Ampicillin 10 67 71
Piperacillin 100 76 71
Piperacillin/tazobactam 100/10 79 65
Carbapenems Imipenem 10 21 17
Meropenem 10 55 41
Cephalosporins Cefepime 30 94 79
Cefixime 30 75 71
Cefotaxime 30 84 87
Ceftazidime 30 76 79
Ceftriaxone 30 82 73
Cefuroxime 30 78 84
Fluoroquinolones Ciprofloxacin 5 78 89
Gatifloxacin 5 82 74
Levofloxacin 5 32 25
Norfloxacin 10 87 75
Ofloxacin 5 79 74
Monobactam Aztreonam 30 83 75
Sulfonamides Co-trimoxazole 25 84 94
Synthetic drug Nitrofurantoin 300 94 86
a Data presented are means of triplicate values; HA, Hospital acquired; CA, Community acquired. Total number of E. coli isolates 1642.
Prevalence of fluoroquinolone resistant E. coli strains506these are the latest generation of broad spectrum antibiotics
used against drug resistant pathogenic bacteria, as well as in
the empiric therapy of critically ill patients.
MIC values
For 50 fluoroquinolone sensitive E. coli strains, it was
found that when ciprofloxacin was used, the MIC range was
0.5e1.0 mg/ml for 33 strains, and the remaining 17 strains
had MIC values of 0.25 mg/ml; similarly, for levofloxacin,
the MIC range was 0.5e1.0 mg/ml for 35 strains, and the
remaining 15 strains had MIC values of 0.25 mg/ml.
Further, with ciprofloxacin, of the 50 fluoroquinolone-Table 2: Detection of MIC values of 50 E. coli isolates in with two
Breakpoint (mg/ml) Ciprofloxacin
FL-S (n ¼ 50) FL-R (
0.25 17 e
0.5 10 e
1 23 e
2 e e
4 e e
8 e 18
16 e 17
32 e e
64 e e
128 e 02
256 e 10
512 e 03
a Fq-S, fluoroquinolone-sensitive; Fq-R, fluoroquinolone-resistant.resistant E. coli strains, 47 isolates had a MIC range of 2e
256 mg/ml, and the remaining three isolates had a MIC value
of 512 mg/ml. Likewise, with levofloxacin, all 44
fluoroquinolone-resistant E. coli strains had a MIC range of
8e256 mg/ml, and the remaining six isolates had aMIC value
of 512 mg/ml (Table 2).
Univariate analysis of fluoroquinolone sensitive and resistant
isolates of E. coli
Univariate analysis of fluoroquinolone sensitive and
resistant isolates of E. coli was performed using four vari-
ables, number of isolates, sex, comorbidities and otherfluoroquinolone antibioticsa.
Levofloxacin
n ¼ 50) FL-S (n ¼ 50) FL-R (n ¼ 50)
15 e
22 e
13 e
e e
e e
e e
e e
e 01
e 17
e 22
e 04
e 06
S. Rath and R.N. Padhy 507infections. For fluoroquinolone-resistant levels and sensitive
level strains as determined from theMIC values, E. coli had a
0.9589 times greater chance of being picked up by any patient
in a hospital setting (Table 3). Males had a 1.0848 times
greater chance of picking up fluoroquinolone-resistant iso-
lates of both bacteria; these values were not statistically
significant. People with non-infectious comorbidities had a
greater chance of picking up fluoroquinolone-resistant iso-
lates. The data recorded for non-infectious or infectious
comorbidities were highly significant for E. coli (p < 0.05)
(Table 3).Discussion
The resistance percentage values clearly supported the
occurrence of ESBL-producing and fluoroquinolone-
resistant strains of E. coli isolates in both hospitals and
community settings. Moreover, resistance to aminoglyco-
sides (amikacin, gentamicin, netillin) and carbapenems
(imipenem and meropenem) was recorded, which would
further complicate the treatment regimen, as these are the
latest generation of broad spectrum antibiotics used against
drug-resistant pathogenic bacteria, as well as in the empiric
therapy of critically ill patients. Resistance percentages of
32e89% were recorded against five fluoroquinolone antibi-
otics and were further confirmed by the MIC values. The
univariate analysis revealed invariably that patients with
other bacterial infections had a relatively higher chance of
picking up fluoroquinolone-resistant strains of E. coli
infection.
Resistance in E. coli is caused mainly by chromosomal
mutations in the quinolone resistance-determining region
(QRDR) of gyrA and gyrB, which encode DNA gyrase
subunits, and parC and parE, which encode topoisomerase
IV subunits. Moreover, plasmid-mediated quinolone-resis-
tant (PMQR) genes have been reported in GN bacteria,
including E. coli. The acquisition of PMQR genes alone re-
sults in a low level of fluoroquinolone resistance and does not
lead to MICs exceeding the breakpoints of these agents.15
The impact of prescribing ciprofloxacin on the emergence
of fluoroquinolones resistance in uropathogenic E. coli was
analysed in 72 general practices in west Ireland. Over a 4.5
year period (from April 2004 to September 2008), suscepti-
bility and prescribing data were collected and analysed by a
multilevel model with ciprofloxacin-resistance as the
outcome and prescribing as the predictor. The analysisTable 3: Univariate analysis of fluoroquinolone-sensitive and resistan
Variables Fq-S Fq-R
Strains CA 243 567
HA 257 575
Sex Male 275 605
Female 225 537
Comorbidities Present 154 686
Absent 346 456
Other infections Present 297 345
Absent 203 797
a Fq-S, fluoroquinolone-sensitive; Fq-R, fluoroquinolone-resistant.
b statistically not significant.revealed that in “mean” practices with one prescription per
month, ciprofloxacin resistance was low (3%), whereas in
practices with 10 prescriptions per month, ciprofloxacin
resistance amounted to 5.5%.16 Similar results were recorded
in patients with UTI monitored over a 6-year period in the
USA.17 In 1999, the initial therapy for UTI was switched to
levofloxacin. Prescriptions increased from 3.1 to 12.7 per
1000 visits; in parallel, fluoroquinolone resistance increased
from 1% to 9%. Risk factors for the acquisition of
fluoroquinolone-resistant E. coli were hospitalization (or
for each week of hospitalization ¼ 2.0), and levofloxacin use
within the previous year (OR-value 5.6). Similar risk factors
were recorded independently from many other countries.9 In
a population-based survey of 3996 persons in Indonesia,
fluoroquinolone-resistant E. coli was prevalent in the faecal
flora of 6% of patients at hospital admission and 23% of
patients at discharge, but not among healthy relatives or
patients visiting primary healthcare centres. Molecular
typing showed extensive genetic diversity with only limited
clonality among isolates. This finding suggested that the in-
dependent selection of resistant mutants occurs frequently.
Fluoroquinolone-resistant isolates exhibited a higher rate of
spontaneous mutation, but low virulence profiles, than FQ-
susceptible isolates from the same population.18
As in several developing countries, there is no ideal anti-
biotic policy in India. Such a study should strengthen the
epidemiological database and would help foster prudent
decisions in the country’s forthcoming antibiotic policies.
Secondly, countries belonging to zones other than Western
Europe and North America would benefit from this study to
estimate the global load of MDR bacteria in terms of
recently used antibiotics, such as carbapenems and fluo-
roquinolones. This matter is an important aspect of global
medicine, as MDR bacteria remain pervasive in communities
and hospitals. The limitation of the study is the lack of
molecular diagnosis of isolated strains, as has been done
elsewhere.15 Thus, the data presented epitomize the daunting
state of the infection-dynamics of fluoroquinolone-resistant
E. coli in hospitals and adjoining communities.
In conclusion, a total of 1642 strains of E. coli were iso-
lated, of which 810 isolates were from CA samples and 832
isolates were from hospitalized patients, in 39 months. Of the
810 CA isolates, 567 strains were resistant to fluoroquinolone
antibiotics; of the 832 HA isolates, 575 strains were
fluoroquinolone-resistant, independently. This clearly indi-
cated that fluoroquinolone resistance was of similar magni-
tude in CA and HA clinical samples. The MIC values oft isolates of E. colia.
p- value Odd ratio Range
0.6954 0.9589 0.7770 e 1.1833b
0.4495 1.0848 0.8784 e 1.3398b
<0.0001 0.2959 0.2365 e 0.3701
<0.0001 3.3799 2.7160 e 4.2060
Prevalence of fluoroquinolone resistant E. coli strains508ciprofloxacin and levofloxacin used in vitro could help the
current/coveted treatment options. Patients with other bac-
terial infections had relatively higher chances of becoming
infected with fluoroquinolone-resistant E. coli strains.
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